Moffitt Cancer Center, a Tampa-based cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, have formed a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives.
The collaboration will combine Moffitt’s clinical capabilities with Fulgent’s nanotherapeutics and genomics platforms to accelerate the development of personalized cancer therapies.
Under the agreement, Moffitt will provide Fulgent with priority access to its clinical expertise and resources, to expedite the advancement of Fulgent’s clinical pipeline.
The partnership will also focus on co-developing next-generation personalized treatment options for cancer.